Last reviewed · How we verify

NCT03614767

Sacral Neuromodulation & Urodynamics

Status unknown Last updated 15 October 2019
What this trial tests

trial testing urodynamics in Overactive Bladder in 100 participants. Status unknown.

Timeline
1 August 2017
Primary endpoint
31 July 2022
31 July 2022

Quick facts

Lead sponsorUniversiteit Antwerpen
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment100
Start date1 August 2017
Primary completion31 July 2022
Estimated completion31 July 2022
Sites1 location across Belgium

Drugs / interventions tested

Conditions studied

Sponsor

Universiteit Antwerpen — full company profile →

Who can join

18 and older, any sex, with Overactive Bladder or Non-obstructive Urinary Retention. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In the field of urology, sacral neuromodulation (SNM) is a well-accepted, second-line, minimally invasive treatment for patients with overactive bladder dry (OABD) or wet (OABW), and for patients with non-obstructive urinary retention (NOUR). Long-term vary between 50-60%. This study examines whether urodynamics can be used as a predictor for successful SNM therapy

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Overactive Bladder

Currently open trials in the same condition.

Other Universiteit Antwerpen trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03614767.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing